Abstract

This study assessed the efficacy and safety of edaravone dexborneol in conjunction with aspirin in managing acute ischemic stroke. A retrospective study was conducted with 128 individuals who were treated for ischemic stroke from February 2019 to June 2023. Based on varying treatment methods, the individuals were categorized into control (n=62) and observation groups (n=66). In the observation group, a combination therapy of edaravone dexborneol and aspirin was administered, while the control group was provided with enteric-coated aspirin. Comparative analysis of the two groups included clinical efficacy, neurological function using National Institutes of Health Stroke Scale, daily living activities, hemorheology parameters (whole blood high shear viscosity, whole blood low shear viscosity and plasma viscosity), serum oxidative stress levels (superoxide dismutase and malondialdehyde), and levels of neuroinjury biomarkers (neuron-specific enolase, specific calcium-binding protein 100-beta. The study also evaluated adverse reactions between the two groups. Significantly higher effectiveness of treatment was observed in the observation group (92.42 %) and control group (72.58 %) (p<0.05). While following the treatment, observation group exhibited a more notable declined in National Institutes of Health Stroke Scale scores and an elevation in activities of daily living scores when compared with the control group (p<0.05). Similarly, the observation group exhibited a notable decline in hemorheology parameters (including whole blood high shear viscosity, whole blood low shear viscosity, and plasma viscosity) when compared to the control group (p<0.05). The observation group displayed a notable decline in serum oxidative stress levels (malondialdehyde) and a considerable elevation in superoxide dismutase levels, compared to the control group (p<0.05). Furthermore, the observation group exhibited a remarkable decline in the levels of neuroinjury biomarkers compared to the control group (p<0.05). Adverse reaction incidence rates of 10.61 % and 9.68 % were observed in the observation group and control group, respectively (p>0.05). In the treatment of acute ischemic stroke, the utilization of edaravone dexborneol in combination with aspirin exhibits positive clinical efficacy and safety.